































































Borri General Thoracic Surgery
G
TSresection of locally advanced lung cancer. J Thorac Cardiovasc Surg.
1995;110:386-95.
6. Ginsberg RJ, Hil LD, Eagan RT. Modern thirty day mortality of
surgical resections in lung cancer. J Thorac Cardiovasc Surg. 1983;
86:654-8.
7. Bernard A, Deschamps C, Allen M, Miller D, Trastek V, Jenkins GD,
Pairolero P. Pneumonectomy for malignant disease: factors affecting
early morbidity and mortality. J Thorac Cardiovasc Surg. 2001;121:
1077-82.
8. Martin J, Ginsberg RJ, Abolhoda A, Bains MS, Downey RJ, Korst RJ
et al. Morbidity and mortality after neoadjuvant therapy for lung
cancer: the risks of right pneumonectomy. Ann Thorac Surg. 2001;72:
1149-54.
9. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, et
al. The American European Consensus Conference on ARDS. Defi-
nitions, mechanisms, relevant outcomes, and clinical trial coordina-
tion. Am J Respir Crit Care Med. 1994;149:818-24.
0. Dartevelle P, Macchiarini P, Chapelier A. Technique of superior vena
cava resection and reconstruction. Chest Surg Clin North Am. 1995;
5:345-58.
1. Amato MB, Barbas CS, Medeiros DM, Magaldi RB, Schettino GP,
Lorenzi-Filho G, et al. Effect of a protective-ventilation strategy on
mortality in the acute respiratory distress syndrome. N Engl J Med.
1998;338:347-54.
2. Di Perna C, Wood DE. Surgical management of T3 and T4 lung
cancer. Clin Cancer Res. 2005;11:5038s-44s.
3. Cetinkaya E, Turna A, Yldiz P, Dodurgali R, Bedirhan MA, Gurses A,
et al. Comparison of clinical and surgical pathologic staging of the
patients with non-small cell lung carcinoma. Eur J Cardiothorac Surg.
2002;22:1000-5.
4. Spaggiari L, Regnard JF, Magdeleinat P, Jauffret B, Puyo B, Levas-
seur P. Extended resections for bronchogenic carcinoma invading the
superior vena cava system. Ann Thorac Surg. 2000;69:233-6.
5. Ratto GB, Costa R, Vassallo G, Alloisio A, Manieri P, Bruzzi P.
Twelve-year experience with left atrial resection in the treatment of
non-small cell lung cancer. Ann Thorac Surg. 2004;78:234-7.
6. Regnard JF, Perotin C, Giovanetti R, Sschussler O, Petino A, Spag-
giari L, et al. Resection for tumor with carenal involvement: technical
aspects, results and prognostic factors. Ann Thorac Surg. 2005;80:
1841-6.
7. Suzuki K, Asamura H, Watanabe S, Tsuchiya R. Combined resection
of superior vena cava for lung carcinoma: prognostic significance of
patterns of superior vena cava invasion. Ann Thorac Surg. 2004;78:
1184-9.
8. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, et
al. Vinorelbine plus cisplatin vs. observation in resected non–small-
cell lung cancer. N Engl J Med. 2005;352:2589-97.
9. Rosell R, Gomez-Codina J, Camps C, Maestre J, Padille J, Canto A, et
al. A randomized trial comparing preoperative chemotherapy plus
surgery with surgery alone in patients with non-small-cell lung cancer.
N Engl J Med. 1994;330:153.
0. Roth JA, Fossella F, Komaki R, Ryan MB, Putnam JB Jr, Lee JS, et
al. A randomized trial comparing perioperative chemotherapy and
surgery with surgery alone in resectable stage IIIA non-small-cell lung
cancer. J Natl Cancer Inst. 1994;86:673.
1. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of
vinorelbine on quality of life and survival of elderly patients with
advanced non-small-cell lung cancer. J Natl Cancer Inst. 1999;91:66.
2. Leo F, Solli P, Veronesi G, Radice D, Floridi A, Gasparri R et al. Does
chemotherapy increase the risk of respiratory complications after
pneumonectomy? J Thorac Cardiovasc Surg. 2006;132:519-23.
3. Leo F, Solli P, Spaggiari L, Veronesi G, De Braud F, Leon ME, et al.
Respiratory function changes after chemotherapy: an additional risk
for post-operative respiratory complication? Ann Thorac Surg. 2004;
77:260-5.
4. Marino P, Preatoni A, Cantoni A. Randomized trials of radiotherapy
alone versus combined chemotherapy and radiotherapy in stage IIIa
and IIIb non-small cell lung cancer. A meta-analysis. Cancer. 1995;
76:593-601. m
The Journal of Thoracic5. Dyszkiewicz W, Piwkowski C, Kasprzyk M, Ramlau R, Adamczak J,
Pawlak K. Extended pneumonectomy for non small cell lung cancer:
should we still do it? Neoplasm. 2004;51:150-4.
iscussion
r Wood. Dr. Veronesi, congratulations on very good work by
ou and your group on a complex group of patients. These are
ifficult patients, and you certainly got good results both in oper-
tive outcomes as well as in survival in a group of patients with
dvanced disease.
I wanted to emphasize a couple of points that were more in
our paper than in the presentation. One was this aspect of clinical
verstaging of T4 disease. In your series you found it 15% of the
ime. There is a series from about four years ago in the European
ournal of Cardiothoracic Surgery that found clinical overstaging
f T4 disease 40% of the time. I think that it is important to
mphasize this experience since often a thoracic surgeon will not
ee these patients because they are clinically staged as T4 and felt
o be unresectable. Or we may see them and deny surgical con-
ideration for the same reason, yet they may really have T2-3
isease due to overstaging. This is one important aspect of looking
t patients with locally advanced disease.
My first question is whether you think there really is a differ-
nce between T3 and T4 disease. You said that was a limitation of
our study, but is there biologically any reason that there is a
ifference between T3 disease and T4 disease, and should we treat
hem any differently if we can achieve a complete resection?
Dr Veronesi. When I say limitation of the study, I mean that
he group of chest wall resection and diaphragm resection doesn’t
each the common definition of extended resections in literature
efinition. Nevertheless, I put this kind of patient in the work
ecause we found that after pneumonectomy they also have a high
ate of complications, so I think very aggressive surgery even in
his case is T3 and T4, T3 diaphragm or chest wall. We included
t for this reason, but the biologic difference I think is not so high,
ecause in both cases I suggest induction chemotherapy. It may be
hat downstaging after chemotherapy may make a T4 become a T3
fter surgical exploration.
Dr Wood. This is another place where we can educate our
edical colleagues that we work with because they often consider
4 to be a contraindication to surgery and biologically the differ-
ntiation is arbitrary. It is arbitrary, based upon a historical surgical
efinition of what we can resect or not, and that is changing.
Your conclusions emphasized the importance of mediastinal
taging and I couldn’t agree with you more. The principles of
uccess in lung cancer surgery are completeness of resection,
hich is more difficult in this group of patients, and nodal status.
t does appear that if these patients also have advanced nodal status
hen they probably are not going to benefit from surgery. I agree
ompletely with you in that regard.
I would respectfully disagree with you about the role of induc-
ion chemotherapy. Most of your patients had induction chemo-
herapy, which prevents you from being able to really compare the
mpact of not having induction chemotherapy or having it. The
urported benefits are trying to decrease the extent of resection or
mprove resectability with negative margins and to treat potential
ystemic disease. These patients do need systemic therapy at some
oint in their treatment but not necessarily before surgery. Che-
otherapy does create the problem of figuring out where the
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TSargins should be because of the chemotherapy response around
umor. You also made the point that induction therapy increases
orbidity and mortality in pneumonectomy, so I guess I would
hallenge you and question: do you really think that we should
ive these patients chemotherapy? We do not have strong evidence
hat it increases resectability. We do have strong evidence that it
ncreases morbidity and mortality. Should we reconsider this con-
lusion from your paper?
Dr Veronesi. In another work we are going to publish, we
ound that induction chemotherapy increased morbidity but finally
ot mortality in pneumonectomy, so we had more than 50 pneu-
onectomies after chemotherapy. The other observation I can
ake is the few long-term survivals in this series had all received
nduction chemotherapy. I know that it is not significant from a
tatistical point of view but it is an observation.
Dr Wood. Yes, but all but nine of your patients had induction
hemotherapy, so it would be hard for it to be otherwise.
Dr Veronesi. The fact that . . . (end of cassette)
Dr Wood. We recommend mediastinoscopy in all of these
atients, not only for identifying nodal disease, but also for min-
mally invasive exploration of the mediastinum. Mediastinoscopy
an help determine the extent of airway involvement or the extent
f pulmonary artery involvement before committing the patient to
thoracotomy, as well as developing some of the tissue planes that
re subsequently useful when you are doing a carinal resection.
re you doing mediastinoscopy at the time of the planned resec-
ion and do you find that same benefit in terms of staging the
ediastinum not just for nodes but for extent of primary tumor?
Dr Veronesi. Not particularly. We use it mostly for nodal
taging and when not positive we perform induction chemotherapy
nd then we don’t perform a redo-mediastinoscopy, so usually it is
long period in advance compared with the surgery.
Dr Wood. Congratulations again on your work. Very nice
resentation and nice paper. Thank you.
Dr Veronesi. Thank you.
Doctor [unidentified]. Thank you so much for giving me the
pportunity to raise some questions. It was a fine presentation, but
or me there remain three questions. The first one, you mentioned
he combination of T3 and T4 patients is a weak point of your
resentation. Why didn’t you exclude T3 patients who have, as we
272 The Journal of Thoracic and Cardiovascular Surgery ● Novll know, the much better prognosis? The second question is, you
entioned four T1 cases. How _____ to explain? And the third
ne, there begins really the atrial resection: all intrapericardial
esections or where is exactly the border?
Dr Veronesi. I’ll start with your final question. The resection
as defined as resection not of the vein but of the wall of the
trium at the pathologic exam, so the muscle layer was present. I
ouldn’t understand your second question, sorry. Could you repeat
t?
Doctor [unidentified]. The second question is, you made a
able with 4 cases in stage T1.
Dr Veronesi. One case. There was 1 case of stage T1.
Doctor [unidentified]. Why do you do an extended pneumo-
ectomy for T1?
Dr Veronesi. It was a case that had a major response to
hemotherapy, so we couldn’t know the tissue viability before the
urgery.
And the first question about T3 and T4, we discussed before
ith Dr. Wood.
Doctor [unidentified]. Yes, but T3 is quite another entity from
4. If you mix it, you ameliorate the prognosis of the patients of
he _____ group. I don’t know whether it is correct or not.
Dr Veronesi. Yes, but maybe some T3 were T4 before induc-
ion chemotherapy, so we never know that.
Dr Doty. I was taken by the sentence in the abstract, “Neither
ostoperative outcome nor survival were significantly influenced
y the type of extended pneumonectomy.” Just to give you a little
erspective on this, my first experience over 40 years ago with the
neumonectomy was with the late George Lindesmith, and it was
large bronchogenic carcinoma originating in the right main
ronchus deep in the mediastinum. I was really determined to have
he opportunity to resect that lung, and George Lindesmith said to
e, “You know, Don, getting out a lung cancer is always possible.
t just depends on how hard you want to work, but it won’t make
ny difference in the end.” And so here we are with 23% survival
n extended pneumonectomies 40 years later. It’s kind of the same,
sn’t it? I mean have we really made any progress on this? I just
eave you to answer that question. You don’t have to. You’re too
oung.Dr Mulligan. Perhaps a question for the group to reflect upon.
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